Recommended Dosing for Typhoid Fever in Adults
For adults with typhoid fever, use azithromycin 500 mg once daily for 7 days as first-line therapy, or cefixime 400 mg once daily for 7-14 days as an alternative, with treatment choice guided by local resistance patterns.
Treatment Algorithm Based on Resistance Patterns
First-Line Recommendations
Azithromycin is the preferred agent based on WHO guidelines and superior clinical outcomes 1:
- Dose: 500 mg (or 20 mg/kg/day, maximum 1 g) orally once daily for 7 days 2, 3
- Shows lower clinical failure rates (OR 0.48) and shorter hospital stays compared to fluoroquinolones 1
- Significantly lower relapse rates (OR 0.09) compared to ceftriaxone 1
- Particularly effective for multidrug-resistant (MDR) and nalidixic acid-resistant strains 3
Alternative: Cefixime
Cefixime serves as an alternative when azithromycin is unavailable or contraindicated 1:
- Dose: 400 mg orally once daily 4
- Duration: 7-14 days (WHO recommends this for MDR strains) 1
- FDA-approved dosing is 400 mg daily, which can be given as a single dose 4
Critical Considerations for Treatment Selection
When to Choose Azithromycin Over Cefixime
The evidence strongly favors azithromycin in most scenarios:
- Nalidixic acid-resistant strains: Azithromycin demonstrates superior fever clearance time (135 hours vs 174 hours with ofloxacin) and better fecal clearance 3
- MDR typhoid: Clinical cure rates of 95.5% with azithromycin versus 86.4% with fluoroquinolones 3
- Shorter treatment duration: 7 days versus 14 days for cefixime reduces compliance issues
When Cefixime May Be Appropriate
- Azithromycin unavailable or contraindicated
- Local resistance patterns favor cephalosporins
- Cost considerations (though this should not compromise outcomes)
Important caveat: Cefixime may have longer fever clearance times (mean difference +1.74 days) and potentially higher failure rates compared to fluoroquinolones in older studies 5, though resistance patterns have evolved significantly.
Resistance-Based Decision Making
The WHO 2003 guidelines provide a resistance-stratified approach 1:
For quinolone-resistant strains (increasingly common in South Asia):
- First choice: Azithromycin
- Second choice: Ceftriaxone (IV, 2-4 g daily)
- Third choice: Cefixime (oral alternative)
For MDR strains (resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole):
- Fluoroquinolones OR cefixime
- Azithromycin as alternative 1
Practical Implementation Points
Dosing Adjustments
Cefixime renal impairment 4:
- CrCl ≥60 mL/min: Normal dose (400 mg daily)
- CrCl 21-59 mL/min: 260 mg daily (13 mL of 100 mg/5 mL suspension)
- CrCl ≤20 mL/min or dialysis: 172 mg daily (8.6 mL of 100 mg/5 mL suspension)
Azithromycin: No specific renal adjustment typically needed for 7-day course, but use caution in severe renal impairment.
Common Pitfalls to Avoid
- Don't substitute cefixime tablets for suspension in otitis media 4 - though this is less relevant for typhoid, it highlights bioavailability differences
- Don't use fluoroquinolones empirically in South Asia without susceptibility data due to widespread resistance 6
- Don't underdose: Ensure full 7-day course of azithromycin; premature discontinuation increases relapse risk
- Don't ignore treatment failure: If fever persists beyond 5-7 days, consider resistance and switch to IV ceftriaxone (2-4 g daily)
Emerging Considerations
Recent evidence suggests combination therapy (azithromycin + cefixime) is being investigated for extensively drug-resistant (XDR) typhoid 7, 6, though this is not yet standard practice. The rationale is targeting both intracellular (azithromycin) and extracellular (cefixime) bacterial populations.
For XDR strains emerging from Pakistan, azithromycin and/or meropenem may be required 6.